

Sharon E Johnatty

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6170314/publications.pdf>

Version: 2024-02-01

53
papers

3,358
citations

279798

23
h-index

206112

48
g-index

54
all docs

54
docs citations

54
times ranked

7123
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between <i>BRCA1</i> and <i>BRCA2</i> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 382.	7.4	546
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
4	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , The, 2013, 14, 853-862.	10.7	335
5	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
6	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884.	21.4	235
7	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	107
8	<i>ABCB1</i> (<i>MDR1</i>) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. <i>Clinical Cancer Research</i> , 2008, 14, 5594-5601.	7.0	90
9	Identification of Genes Regulated During Mechanical Load-induced Cardiac Hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 805-815.	1.9	75
10	Consortium analysis of 7 candidate SNPs for ovarian cancer. <i>International Journal of Cancer</i> , 2008, 123, 380-388.	5.1	73
11	Platinum Sensitivity-Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5490-5500.	7.0	57
12	<i>ABCB1</i> (<i>MDR1</i>) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14.	1.4	55
13	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility "Hot-Spot". <i>PLoS Genetics</i> , 2010, 6, e1001016.	3.5	48
14	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. <i>PLoS ONE</i> , 2011, 6, e24987.	2.5	48
15	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. <i>Clinical Cancer Research</i> , 2011, 17, 3742-3750.	7.0	47
16	β_2 adrenergic receptor 5' haplotypes influence promoter activity. <i>British Journal of Pharmacology</i> , 2002, 137, 1213-1216.	5.4	44
17	Progesterone receptor polymorphisms and risk of breast cancer: results from two Australian breast cancer studies. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 91-99.	2.5	35
18	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. <i>Clinical Cancer Research</i> , 2015, 21, 5264-5276.	7.0	33

#	ARTICLE	IF	CITATIONS
19	Co-existence of leiomyomas, adenomyosis and endometriosis in women with endometrial cancer. <i>Scientific Reports</i> , 2020, 10, 3621.	3.3	33
20	Assessment of Hepatocyte Growth Factor in Ovarian Cancer Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1638-1648.	2.5	31
21	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. <i>Gynecologic Oncology</i> , 2017, 147, 381-387.	1.4	30
22	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. <i>Oncotarget</i> , 2016, 7, 6353-6368.	1.8	29
23	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. <i>Scientific Reports</i> , 2014, 4, 4669.	3.3	24
24	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018, 93, 307-320.	3.0	22
25	Large-Scale Evaluation of Common Variation in Regulatory T Cell-Related Genes and Ovarian Cancer Outcome. <i>Cancer Immunology Research</i> , 2014, 2, 332-340.	3.4	21
26	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 987-992.	2.5	20
27	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. <i>Cancer Causes and Control</i> , 2017, 28, 459-468.	1.8	20
28	The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysis. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 145-150.	2.5	19
29	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	1.4	18
30	No evidence for an association between the earwax-associated polymorphism in ABCC11 and breast cancer risk in Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 235-239.	2.5	16
31	The MnSOD Val9Ala polymorphism, dietary antioxidant intake, risk and survival in ovarian cancer (Australia). <i>Gynecologic Oncology</i> , 2007, 107, 388-391.	1.4	15
32	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. <i>Gynecologic Oncology</i> , 2020, 158, 702-709.	1.4	15
33	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
34	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 371-379.	2.5	12
35	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 780-790.	2.5	10
36	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 446-454.	2.5	9

#	ARTICLE	IF	CITATIONS
37	Risk and prognostic factors for endometrial carcinoma after diagnosis of breast or Lynch-associated cancers—A population-based analysis. <i>Cancer Medicine</i> , 2018, 7, 6411-6422.	2.8	9
38	Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. <i>Twin Research and Human Genetics</i> , 2009, 12, 269-275.	0.6	8
39	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. <i>Twin Research and Human Genetics</i> , 2012, 15, 615-623.	0.6	8
40	Generating high-quality data abstractions from scanned clinical records: text-mining-assisted extraction of endometrial carcinoma pathology features as proof of principle. <i>BMJ Open</i> , 2020, 10, e037740.	1.9	7
41	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. <i>Oncotarget</i> , 2017, 8, 64670-64684.	1.8	7
42	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1669-1680.	2.5	5
43	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. <i>PLoS ONE</i> , 2011, 6, e19642.	2.5	5
44	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 420-424.	2.5	3
45	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 1508.	3.3	3
46	Case-case analysis addressing ascertainment bias for multigene panel testing implicates <i>BRCA1</i> and <i>PALB2</i> in endometrial cancer. <i>Human Mutation</i> , 2021, 42, 1265-1278.	2.5	3
47	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. <i>Cancers</i> , 2022, 14, 1954.	3.7	3
48	Letter to the editor re: “Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome?” from T. Song and colleagues. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2016, 198, 153-155.	1.1	0
49	Abstract 4679: A multi-stage genome-wide association study on response to chemotherapy in ovarian cancer. , 2011, , .		0
50	Abstract A55: Influence of ABCB1 polymorphisms on paclitaxel pharmacokinetics in ovarian cancer patients. , 2013, , .		0
51	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5563-5563.	1.6	0
52	Abstract 3286: Identification of genetic loci associated with ovarian cancer prognosis. , 2014, , .		0
53	Abstract 5493: Genome-wide study of carboplatin and paclitaxel disposition in ovarian cancer patients. , 2015, , .		0